The Schall Law Firm is actively recruiting investors who purchased REGENXBIO Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026 to participate in an ongoing securities fraud class action lawsuit. The litigation centers on allegations that the company made materially false and misleading statements regarding its lead product candidate, RGX-111, while allegedly withholding critical efficacy and safety data from the investment community.
According to the lawsuit, REGENXBIO presented substantially positive public statements about RGX-111 despite internal knowledge of adverse trial results and safety concerns. The legal action was catalyzed when the company disclosed that a study participant had developed an intraventricular CNS tumor during clinical evaluation of the therapy. This revelation prompted scrutiny of the company's prior disclosure practices and communications to shareholders during the specified period.
Investors seeking to join the class action must initiate contact with the Schall Law Firm before the April 14, 2026 deadline. The firm is reviewing the company's public filings, regulatory submissions, and press releases during the relevant timeframe to substantiate claims of inadequate disclosure regarding the product candidate's clinical profile.